Study
Spermidine Supplementation May Boost Vaccine Response in Older Adults
Daily spermidine supplements improved vaccine responses in some seniors, especially those with weaker initial responses.
Summary
In plain language
Researchers found that taking a daily 6 mg spermidine supplement helped improve vaccine responses in older adults. This was especially true for those who initially had a weaker response to vaccines. Spermidine, a compound found in foods like wheat germ, seems to enhance the body's ability to fight infections by improving immune cell function. This study suggests that spermidine could be a safe way to help older adults get better protection from vaccines. It's important for seniors to discuss with their doctors whether spermidine supplements might be beneficial for them.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study was a randomized controlled trial involving older adults who received a daily spermidine supplement after their COVID-19 booster shot. Researchers measured immune responses to see if spermidine could enhance vaccine effectiveness.
The study found that spermidine improved immune responses in participants who initially had low vaccine responses, suggesting it may help boost immunity in older adults.
While the supplement was safe and well-tolerated, the study had a small sample size, which means more research is needed to confirm these findings.
For seniors, this research highlights a potential way to improve vaccine effectiveness, but it's important to talk to healthcare providers before starting any new supplement.
Discussing these findings with a healthcare provider can help determine if spermidine is a good option for you.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Spermidine Supplementation May Boost Vaccine Response in Older Adults
Published November 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored November 9, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study scored well in study design due to its RCT nature. Bias control was moderate due to lack of blinding details. Statistical integrity was limited by the exploratory nature and lack of power. Transparency was partial with registration but no data sharing. Conflicts were disclosed but involved industry funding. The study is relevant to the target population, but journal quality could not be assessed.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 6.7/10 | |
| Statistical methods | 5.0/10 | |
| Reporting completeness | 5.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 10.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This randomized controlled trial evaluated the safety and effects of spermidine supplementation on vaccine responses in older adults. It found that spermidine may enhance vaccine responses in non-responders by reducing immune cell senescence.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.